Gvax (Not yet branded)
Other Medications
Description
GVAX is an allogeneic cellular cancer vaccine composed of irradiated colon cancer cells that have been genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF). This immunotherapy approach is designed to stimulate the patient's immune system to recognize and attack colorectal cancer cells by presenting tumor-associated antigens in an immunogenic context. GVAX is being tested in combination with immune checkpoint inhibitors like pembrolizumab and DNA methyltransferase inhibitors such as SGI-110, particularly in mismatch repair-proficient colorectal cancers that typically respond poorly to standard immunotherapy.
Mechanism of Action
The genetically modified colon cancer cells in GVAX secrete GM-CSF, which recruits and activates dendritic cells and other antigen-presenting cells at the vaccination site. These immune cells then process tumor antigens from the irradiated cancer cells and present them to T-cells, promoting a targeted immune response against similar antigens found on the patient's own colorectal cancer cells.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | Subcutaneous |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.